Opko Health Inc. (OPK)
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?
OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, supported by the potential of RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE's performance and strategic partnerships.
OPKO Health: Deeply Mispriced Ahead Of Major Catalysts
I believe OPKO Health will end 2026 on a high note. In partnership with Merck, Regeneron, and BARDA, it is developing ModeX's product candidates aimed at treating COVID-19, influenza, solid tumors, and blood cancers, as well as vaccines against EBV. Additionally, OPKO's balance sheet continues to strengthen, with total debt reaching $395.4 million at the end of Q3, down 22.8% year-over-year.
OPKO Health, Inc. (OPK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
OPKO Health, Inc. (OPK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth
OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now
OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.
OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands
OPKO Health's Q3 earnings top estimates despite lower sales. Cost cuts and product strength boost margins and operating income.
OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript
OPKO Health, Inc. ( OPK ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Phillip Frost - Chairman & CEO Elias Zerhouni - President & Vice Chairman Adam Logal - Senior VP & CFO Gary Nabel - Chief Information Officer & Director Conference Call Participants Yvonne Briggs - LHA Investor Relations Maurice Raycroft - Jefferies LLC, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) Q3 Earnings Surpass Estimates
OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
Here's Why You Should Add OPKO Health Stock to Your Portfolio
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands
OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.
